There is no certainty that the buyout will come to pass, according to The Financial Times, which first reported the rumors.

Wells Fargo raised the firm’s price target on Avidity Biosciences (RNA) to $75 from $70 and keeps an Overweight rating on the shares. The firm ...

SERB Pharmaceuticals plans to buy Y-mAbs Pharmaceuticals in a $412 million all-cash deal. CorMedix bought Melinta ...

Exact Sciences stock crashed Thursday as the Street debated the merits of its licensing deal for a blood-based colon cancer ...